OraSure Confirms Altai Capital Nominates Board Candidates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy OSUR?
OraSure Technologies confirmed that Altai Capital has nominated two candidates, including the fund's founder Rishi Bajaj, to stand for election to the company's board at its 2026 Annual Meeting of Stockholders, stating: "As previously announced, OraSure's Board has engaged extensively with Altai Capital. The Board interviewed Mr. Bajaj for potential service on the Board and ultimately decided to appoint an alternative candidate to serve as a director at OraSure. Since that time, Altai has not accepted the Board's offers to make certain of its directors available to engage further. OraSure maintains a strong, independent, and engaged Board. We continually assess our Board composition, and as a result our Board has undergone significant refreshment, bringing in industry perspectives and executive-level experience to provide oversight as management drives growth and value creation... The Nominating and Corporate Governance Committee and OraSure's Board will review Altai's nominations, and the Board will present its recommendation in the Company's definitive proxy statement to be filed with the Securities and Exchange Commission and mailed to stockholders eligible to vote at the Company's 2026 Annual Meeting of Stockholders, which has not yet been scheduled. OraSure shareholders are not required to take any action at this time."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OSUR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OSUR
About OSUR
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OraSure Partners with Altai Capital, Appoints John D. Bertrand to Board
- Board Transformation: OraSure has entered into a cooperation agreement with activist investor Altai Capital, appointing John D. Bertrand to the board, aiming to enhance governance through regular discussions on financial and strategic matters, thereby boosting investor confidence.
- Shareholder Voting Plan: The company plans to seek shareholder approval to declassify its board at the 2026 annual meeting, a move that will improve board transparency and accountability, potentially attracting more investor interest.
- Activist Investor Impact: Following the agreement, Altai Capital withdrew its director nominations, indicating an improving relationship with OraSure that could facilitate sustainable value growth for the company in the future.
- Potential Acquisition Call: Altai reiterated its call for a potential sale of OraSure last month, suggesting that such a move could potentially double the medical device maker's share price, further driving the company's strategic transformation and market performance.
See More
OraSure Appoints New Director and Seeks Shareholder Approval
- New Board Member: OraSure Technologies has appointed John D. Bertrand as an independent director, bringing over a decade of experience in healthcare technology, particularly in AI-driven diagnostics, which is expected to enhance the company's strategic development and market competitiveness.
- Shareholder Meeting Proposal: The company plans to seek shareholder approval to declassify the Board at the 2026 Annual Meeting, aiming to strengthen corporate governance, enhance transparency, and increase shareholder engagement, thereby laying a foundation for long-term value creation.
- Cooperation Agreement Reached: OraSure has entered into a Cooperation Agreement with Altai Capital, where Altai will withdraw its director nominations and engage in regular discussions with OraSure's management on financial and strategic matters, reflecting a positive interaction in corporate governance.
- Advisory Team Support: Evercore is serving as the financial advisor, Goodwin Procter LLP as the legal advisor, and Joele Frank, Wilkinson Brimmer Katcher as the strategic communications advisor, ensuring professional support for the company's governance and strategic implementation.
See More
Surge in Options Trading Volume for OraSure and Viridian
- OraSure Options Volume: OraSure Technologies Inc. experienced options trading volume of 3,510 contracts, representing approximately 351,000 shares, which is about 62.6% of its average daily trading volume of 560,775 shares over the past month, indicating heightened market interest in its future performance.
- High Demand for Call Options: Notably, the $2.50 strike call option expiring on April 17, 2026, saw trading of 3,500 contracts today, representing around 350,000 shares, suggesting investor optimism regarding OraSure's prospects.
- Viridian Options Volume: Viridian Therapeutics Inc. recorded options trading volume of 14,194 contracts, equating to approximately 1.4 million shares, or about 61% of its average daily trading volume of 2.3 million shares over the past month, reflecting strong investor interest in the company.
- Active Trading of Put Options: Particularly, the $14 strike put option expiring on May 15, 2026, has seen trading of 5,002 contracts today, representing approximately 500,200 shares, indicating market concerns regarding potential risks facing Viridian in the future.
See More
Altai Capital Urges Sale of OraSure Technologies to Boost Share Price
- Share Price Potential: Altai Capital is advocating for a potential sale of OraSure Technologies, suggesting a share price valuation between $4.54 and $6.60, representing a premium of 42% to 107% over the current price, indicating significant value in a sale scenario.
- Board Nominations: Altai Capital is reiterating its call for the inclusion of its President Rishi Bajaj and Digital Diagnostics CEO John Bertrand on OraSure's board, aiming to steer the company towards a strategic direction that could enhance its market valuation.
- Acquisition Interest: Healthcare entrepreneur Ron Zwanziger has reconfirmed his interest in acquiring OraSure, having previously proposed an all-cash deal valued at $3.50 to $4.00 per share, highlighting ongoing market interest in the company.
- Market Reaction: Despite the acquisition proposals generating attention, OraSure's shares fell by 2.9%, reflecting market uncertainty regarding the company's future prospects, which may impact investor confidence.
See More
Altai Capital Calls for Board Change at OraSure Technologies
- Shareholder Value Erosion: Altai Capital Management, holding approximately 5% of OraSure's shares, highlights the company's significant underperformance over five and ten years, with management's strategic failures resulting in a 60% loss for shareholders, necessitating board changes to protect investor value.
- Lack of Accountability: Independent directors at OraSure own less than 1% of shares yet receive over $250,000 annually, lacking financial risk for decisions that have harmed shareholder value, prompting Altai to argue for greater shareholder representation on the board.
- Misalignment of Executive Compensation: Over 90% of CEO Carrie Eglinton Manner's compensation is not linked to stock performance, with her total earnings reaching $15 million since 2023 while shareholders have suffered substantial losses, indicating a severe disconnect between executive incentives and shareholder interests.
- Need for Strategic Review: Altai calls for a comprehensive strategic review of OraSure, including the potential sale of the entire business, to ensure optimal returns for shareholders, pledging to advocate for all shareholder interests upon board appointment.
See More
OraSure Technologies Q4 2025 Earnings Call Insights
- Financial Performance Overview: OraSure reported total revenue of $26.8 million in Q4 2025, with core revenue at $26.7 million, driven by $15.1 million from Diagnostic Products and $9.1 million from Sample Management Solutions, while gross margin improved to 41%, reflecting the company's efforts to stabilize revenue.
- Product Launch Plans: The company plans to launch two new products in mid-2026, including a rapid molecular self-test and an at-home urine collection device, marking significant milestones in its innovation roadmap and expected to drive future revenue growth.
- International Market Expansion: OraSure expanded its presence in Canada with the launch of the OraQuick HIV Self-Test and signed framework agreements with 14 African countries, highlighting the company's focus on global markets and their growth potential.
- Future Outlook: The CFO projected that new product launches in the second half of 2026 will drive revenue growth, and despite regulatory uncertainties, the company remains committed to achieving profitable growth through cost control and operational efficiency improvements.
See More
OraSure Partners with Altai Capital, Appoints John D. Bertrand to Board
- Board Transformation: OraSure has entered into a cooperation agreement with activist investor Altai Capital, appointing John D. Bertrand to the board, aiming to enhance governance through regular discussions on financial and strategic matters, thereby boosting investor confidence.
- Shareholder Voting Plan: The company plans to seek shareholder approval to declassify its board at the 2026 annual meeting, a move that will improve board transparency and accountability, potentially attracting more investor interest.
- Activist Investor Impact: Following the agreement, Altai Capital withdrew its director nominations, indicating an improving relationship with OraSure that could facilitate sustainable value growth for the company in the future.
- Potential Acquisition Call: Altai reiterated its call for a potential sale of OraSure last month, suggesting that such a move could potentially double the medical device maker's share price, further driving the company's strategic transformation and market performance.
See More
OraSure Appoints New Director and Seeks Shareholder Approval
- New Board Member: OraSure Technologies has appointed John D. Bertrand as an independent director, bringing over a decade of experience in healthcare technology, particularly in AI-driven diagnostics, which is expected to enhance the company's strategic development and market competitiveness.
- Shareholder Meeting Proposal: The company plans to seek shareholder approval to declassify the Board at the 2026 Annual Meeting, aiming to strengthen corporate governance, enhance transparency, and increase shareholder engagement, thereby laying a foundation for long-term value creation.
- Cooperation Agreement Reached: OraSure has entered into a Cooperation Agreement with Altai Capital, where Altai will withdraw its director nominations and engage in regular discussions with OraSure's management on financial and strategic matters, reflecting a positive interaction in corporate governance.
- Advisory Team Support: Evercore is serving as the financial advisor, Goodwin Procter LLP as the legal advisor, and Joele Frank, Wilkinson Brimmer Katcher as the strategic communications advisor, ensuring professional support for the company's governance and strategic implementation.
See More
Surge in Options Trading Volume for OraSure and Viridian
- OraSure Options Volume: OraSure Technologies Inc. experienced options trading volume of 3,510 contracts, representing approximately 351,000 shares, which is about 62.6% of its average daily trading volume of 560,775 shares over the past month, indicating heightened market interest in its future performance.
- High Demand for Call Options: Notably, the $2.50 strike call option expiring on April 17, 2026, saw trading of 3,500 contracts today, representing around 350,000 shares, suggesting investor optimism regarding OraSure's prospects.
- Viridian Options Volume: Viridian Therapeutics Inc. recorded options trading volume of 14,194 contracts, equating to approximately 1.4 million shares, or about 61% of its average daily trading volume of 2.3 million shares over the past month, reflecting strong investor interest in the company.
- Active Trading of Put Options: Particularly, the $14 strike put option expiring on May 15, 2026, has seen trading of 5,002 contracts today, representing approximately 500,200 shares, indicating market concerns regarding potential risks facing Viridian in the future.
See More
Altai Capital Urges Sale of OraSure Technologies to Boost Share Price
- Share Price Potential: Altai Capital is advocating for a potential sale of OraSure Technologies, suggesting a share price valuation between $4.54 and $6.60, representing a premium of 42% to 107% over the current price, indicating significant value in a sale scenario.
- Board Nominations: Altai Capital is reiterating its call for the inclusion of its President Rishi Bajaj and Digital Diagnostics CEO John Bertrand on OraSure's board, aiming to steer the company towards a strategic direction that could enhance its market valuation.
- Acquisition Interest: Healthcare entrepreneur Ron Zwanziger has reconfirmed his interest in acquiring OraSure, having previously proposed an all-cash deal valued at $3.50 to $4.00 per share, highlighting ongoing market interest in the company.
- Market Reaction: Despite the acquisition proposals generating attention, OraSure's shares fell by 2.9%, reflecting market uncertainty regarding the company's future prospects, which may impact investor confidence.
See More
Altai Capital Calls for Board Change at OraSure Technologies
- Shareholder Value Erosion: Altai Capital Management, holding approximately 5% of OraSure's shares, highlights the company's significant underperformance over five and ten years, with management's strategic failures resulting in a 60% loss for shareholders, necessitating board changes to protect investor value.
- Lack of Accountability: Independent directors at OraSure own less than 1% of shares yet receive over $250,000 annually, lacking financial risk for decisions that have harmed shareholder value, prompting Altai to argue for greater shareholder representation on the board.
- Misalignment of Executive Compensation: Over 90% of CEO Carrie Eglinton Manner's compensation is not linked to stock performance, with her total earnings reaching $15 million since 2023 while shareholders have suffered substantial losses, indicating a severe disconnect between executive incentives and shareholder interests.
- Need for Strategic Review: Altai calls for a comprehensive strategic review of OraSure, including the potential sale of the entire business, to ensure optimal returns for shareholders, pledging to advocate for all shareholder interests upon board appointment.
See More
OraSure Technologies Q4 2025 Earnings Call Insights
- Financial Performance Overview: OraSure reported total revenue of $26.8 million in Q4 2025, with core revenue at $26.7 million, driven by $15.1 million from Diagnostic Products and $9.1 million from Sample Management Solutions, while gross margin improved to 41%, reflecting the company's efforts to stabilize revenue.
- Product Launch Plans: The company plans to launch two new products in mid-2026, including a rapid molecular self-test and an at-home urine collection device, marking significant milestones in its innovation roadmap and expected to drive future revenue growth.
- International Market Expansion: OraSure expanded its presence in Canada with the launch of the OraQuick HIV Self-Test and signed framework agreements with 14 African countries, highlighting the company's focus on global markets and their growth potential.
- Future Outlook: The CFO projected that new product launches in the second half of 2026 will drive revenue growth, and despite regulatory uncertainties, the company remains committed to achieving profitable growth through cost control and operational efficiency improvements.
See More
